ScholarIQanswers from OpenAlex

Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes

PaperCitations, authors & open-access status

Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes have?

ScholarIQcitation count

Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes has 407 citations in the OpenAlex counts ScholarIQ stores.

When was Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes published?

ScholarIQyear

Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes has 2004 year in the ScholarIQ index.

What is the open-access status of Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes?

ScholarIQoa status

Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes has bronze oa status in the ScholarIQ index.

What is the DOI of Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes?

ScholarIQdoi

The DOI for Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes is on the source record.

What is the PMID of Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes?

ScholarIQpmid

The PMID for Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes is on the source record.

What is the OpenAlex record for Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes?

ScholarIQopenalex

The OpenAlex for Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial